BLMH.c shows promising PA ahead of new quarterly results. Since the stock hit bi-yearly lows in May/June, Bloom Health Partners (CSE: BLMH) shares have retained a 64% price rebound and have begun consolidation along the 50MA.
Updates regarding FQ3 performance are expected to be a big catalyst for BLMH in the near future. The company’s FQ2 report showed revenue of $11.1 million, which surpasses its current MCAP by $1.9 million. At the time of the report, YTD revenue equaled $16.9 million, showing even more considerable under-valuation of the company.
If BLMH is able to show consistent growth for FQ3, I expect we will see a very strong price move as the market appears to be awaiting this news given the current price action. The quarterly report is expected within the next couple of weeks, so keep your eyes peeled.
BLMH.c is currency trading at $.195, valued at $9.22 million.
https://ceo.ca/@newsfile/bloom-health-partners-reports-profitable-fiscal-q2